Skip to main content
Top
Published in: Journal of Hematopathology 3/2019

01-09-2019 | Primary Myelofibrosis | Case Report

Co-occurrence of CALR and MPL somatic mutations in an Indian patient with a Philadelphia-negative myeloproliferative neoplasm

Authors: Ketki Kelkar, Vijay Ramanan, Siddharth Anand, Shatakshi Ranade, Kunal Patil, Meenal Agarwal, Nikhil Phadke

Published in: Journal of Hematopathology | Issue 3/2019

Login to get access

Abstract

Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of clonal disorders that are characterized by excessive proliferation of abnormal myeloid precursors and mature cells. Somatic driver mutations in the JAK2, CALR, and MPL genes serve as major diagnostic criteria in the classification of the MPNs, namely polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Although initially thought to be mutually exclusive, recent studies have reported the co-existence of JAK2, MPL, and CALR mutations. In this case report, we describe a case of a Philadelphia-negative myeloproliferative neoplasm harboring mutations in the CALR [NM_004343.3:c.1092_1143del52 (NP_004334.1:p.Leu367Thrfs)] and MPL [NM_005373.2:c.1543T>A (NP_005364.1:p.Try515Arg)] genes. Given the rarity of documented co-occurrence of driver mutations in these two genes and the concomitant paucity of data regarding management of patients harboring mutations in both these genes simultaneously, there are no clear guidelines for the treatment of patients with these mutation patterns and hence it is difficult to assess the true relevance of this genotype. The fact that both the MPL and CALR genes are a part of the JAK-STAT pathway could, however, assist in the clinical decision-making process.
Literature
1.
go back to reference Frawley T, O’Brien C, Conneally E et al (2018) Development of a targeted next-generation sequencing assay to detect diagnostically relevant mutations of JAK2, CALR, and MPL in myeloproliferative neoplasms. Genet Test Mol Biomarkers 22:98–103CrossRefPubMed Frawley T, O’Brien C, Conneally E et al (2018) Development of a targeted next-generation sequencing assay to detect diagnostically relevant mutations of JAK2, CALR, and MPL in myeloproliferative neoplasms. Genet Test Mol Biomarkers 22:98–103CrossRefPubMed
2.
go back to reference McGaffin G, harper K, Stirling D et al (2014) JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Hematol 167:276–278CrossRef McGaffin G, harper K, Stirling D et al (2014) JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Hematol 167:276–278CrossRef
3.
go back to reference Kang MG, Choi HW, Lee JH et al (2016) Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget 7:57036–57049PubMedPubMedCentral Kang MG, Choi HW, Lee JH et al (2016) Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget 7:57036–57049PubMedPubMedCentral
4.
go back to reference Rashid M, Ahmed Z, Ahmed S et al (2016) Coexisting JAK2V617F and CALR exon 9 mutation in essential thrombocythaemia. Indian J Hematol Blood Transfus 32:112–116CrossRefPubMedPubMedCentral Rashid M, Ahmed Z, Ahmed S et al (2016) Coexisting JAK2V617F and CALR exon 9 mutation in essential thrombocythaemia. Indian J Hematol Blood Transfus 32:112–116CrossRefPubMedPubMedCentral
5.
go back to reference Cleyrat C, Chabot-Richards DS, Lynch DT et al (2017) Leukemic transformation of post-essential thrombocythemia myelofibrosis: a unique case presenting with double MPL and CALR mutations. Blood 130:4215 Cleyrat C, Chabot-Richards DS, Lynch DT et al (2017) Leukemic transformation of post-essential thrombocythemia myelofibrosis: a unique case presenting with double MPL and CALR mutations. Blood 130:4215
6.
go back to reference Jeromin S, Meggendorfer M, Fasan A et al (2017) Frequency of concurrent BCR-ABL1, JAK2, CALR and MPL mutations in a cohort of 5,545 cases with suspected MPN by a deep sequencing approach. EHA Learn Center 2017:181088 Jeromin S, Meggendorfer M, Fasan A et al (2017) Frequency of concurrent BCR-ABL1, JAK2, CALR and MPL mutations in a cohort of 5,545 cases with suspected MPN by a deep sequencing approach. EHA Learn Center 2017:181088
7.
go back to reference Usseglio F, Beaufils N, Calleja A et al (2017) Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential thrombocythaemia. J Mol Diagn 91:92–98CrossRef Usseglio F, Beaufils N, Calleja A et al (2017) Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential thrombocythaemia. J Mol Diagn 91:92–98CrossRef
8.
go back to reference Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S (2018) The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol 97:2071–2080CrossRefPubMed Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S (2018) The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol 97:2071–2080CrossRefPubMed
9.
go back to reference De Roeck L, Michaux L, Debackere K et al (2018) Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Hematology 23:785–792CrossRefPubMed De Roeck L, Michaux L, Debackere K et al (2018) Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Hematology 23:785–792CrossRefPubMed
10.
go back to reference Mansier O, Paz DL, Lanotto JC et al (2018) Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol 93:E84–E109CrossRefPubMed Mansier O, Paz DL, Lanotto JC et al (2018) Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol 93:E84–E109CrossRefPubMed
11.
go back to reference Ramanan V, Kelkar K, Ranade S et al (2016) The clinical utility of a custom-developed targeted next-generation sequencing assay for detection of mutations associated with Philadelphia negative chronic myeloproliferative neoplasms: two case examples with CALR exon 9 mutations. Int J MolImmunoOncol 1:28–34 Ramanan V, Kelkar K, Ranade S et al (2016) The clinical utility of a custom-developed targeted next-generation sequencing assay for detection of mutations associated with Philadelphia negative chronic myeloproliferative neoplasms: two case examples with CALR exon 9 mutations. Int J MolImmunoOncol 1:28–34
13.
go back to reference Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8:15CrossRefPubMedPubMedCentral Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8:15CrossRefPubMedPubMedCentral
14.
go back to reference Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F (2014) Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89:E121–E124CrossRefPubMed Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F (2014) Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89:E121–E124CrossRefPubMed
15.
go back to reference Pietra D, Rumi E, Ferretti VV, Buduo CAD, Milanesi C, Cavalloni C, Sant’Antonio E, Abbonante V, Moccia F, Casetti IC, Bellini M, Renna MC, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola M (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30:431–438CrossRefPubMed Pietra D, Rumi E, Ferretti VV, Buduo CAD, Milanesi C, Cavalloni C, Sant’Antonio E, Abbonante V, Moccia F, Casetti IC, Bellini M, Renna MC, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola M (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30:431–438CrossRefPubMed
16.
go back to reference Defour JP, Chachoua I, Pecquet C, Constantinescu SN (2016) Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms. Leukemia 30:1214–1216CrossRefPubMed Defour JP, Chachoua I, Pecquet C, Constantinescu SN (2016) Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms. Leukemia 30:1214–1216CrossRefPubMed
Metadata
Title
Co-occurrence of CALR and MPL somatic mutations in an Indian patient with a Philadelphia-negative myeloproliferative neoplasm
Authors
Ketki Kelkar
Vijay Ramanan
Siddharth Anand
Shatakshi Ranade
Kunal Patil
Meenal Agarwal
Nikhil Phadke
Publication date
01-09-2019
Publisher
Springer Berlin Heidelberg
Published in
Journal of Hematopathology / Issue 3/2019
Print ISSN: 1868-9256
Electronic ISSN: 1865-5785
DOI
https://doi.org/10.1007/s12308-019-00359-7

Other articles of this Issue 3/2019

Journal of Hematopathology 3/2019 Go to the issue